Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)

计划入组 1,240 人 · 首次发布于 2018 年 10 月 30 日

Emulation of the KEYNOTE-189 Trial Using Electronic Health Records

计划入组 1,854 人 · 首次发布于 2023 年 6 月 18 日

Pembrolizumab in Advanced Solid Tumors Analyzed for Predictive Biomarkers (KEYNOTE 158)

计划入组 2 人

K-756

EVO-756

TAK-756

Asher Biotherapeutics, Inc.

United States

Osmotica Pharmaceutical Corp.

United States

Kenota Inc.

Canada

Landmark Breast Cancer Trials Reshape Treatment Paradigms for HR-positive, HER2-negative Disease

Advancements in Targeted Therapies Improve Survival in Breast Cancer

Merck Discontinues Phase 3 Trials of Pembrolizumab in NSCLC and CSCC